Connect With ERS @ AUTM
Your journey with CRISPR begins with a license from ERS Genomics.
Connect with ERS, AUTM 2023
We are delighted to attend and participate in AUTM 2023.
ERS is the world’s leader in licensing of CRISPR/Cas9 technology for a wide variety of applications.
We know that the CRISPR licensing landscape can seem confusing, but we’re here to help provide specific information relevant to technology transfer offices and academic environments.
We provide commercial and custom licenses for Universities. These are accessible CRISPR/Cas9 licenses expressly designed for Tech Transfer offices and academic environments.
If you are currently or planning to provide commercial services or licensing of CRISPR/Cas9 modified cells, animal models, antibodies, proteins, enzymes or any other products,
You will need a license if:
- Your institution has core facilities or labs that perform commercial services.
- Your technology transfer office licenses CRISPR edited products.
- Your institution has start-up companies using CRISPR technology.
Let’s schedule a meeting and discuss how ERS might be able to help you.
Jon Kratochvil
Vice President Business Development & Licensing for North America
Licensing
Intellectual Property
Knowledge Centre
Contact US
The facts about CRISPR/Cas9 Licensing
When it comes to the CRISPR/Cas9 patent licensing landscape there is a lot of misinformation in circulation. Here, we provide straightforward answers to some of the most common misperceptions…
CRISPR/Cas9 For Rapid Vaccine Development
The application of CRISPR/Cas9 provides a novel platform in the development of recombinant viral vaccines through improvements in vaccine design and experimental vaccination approaches across…
CRISPR/Cas9 for Therapeutic Protein Production
Monoclonal antibodies (mAbs), as well as their derivative products including antibody-drug conjugates, Fc-fusion proteins, and antibody fragments, are well recognized for their vast range of therapeutic and diagnostic uses…